Piperazinyltriazines as estrogen receptor modulators

Details Piperazinyltriazines as estrogen receptor modulators Piperazinyltriazines as estrogen receptor modulators

2005-09-13

2005-09-13

Balasubramanian, Venkataraman (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C544S198000, C544S207000, C544S209000

Reexamination Certificate

active

06943162

ABSTRACT:
Triazine derivatives of formula (I), which exhibit pharmacological activity at estrogen receptors alpha (ER alpha) and beta (ER beta) are described herein. The described invention also includes compositions and medicaments containing the triazine derivatives as well as processes for the preparation and use of such compounds, compositions and medicaments.

REFERENCES:
patent: 6117996 (2000-09-01), Lowe et al.
patent: 0 629 622 (1994-12-01), None
patent: 97/10887 (1997-03-01), None
Cecil Textbook of Medicine, edited by Bennet, J.C., and Plum F., 20th edition,vol. 1, 1004-1010, 1996.
Wolft Manfred E. “Burger's Medicinal Chemistry, 5ed, Part 1”, John Wiley & Sons, 1995, pp. 975-977.
Banker, G.S. et al, “Modern Pharmaceutices, 3ed.”, Marcel Dekker, New York. 1996, p. 596.
West, Anthony R., Solid State Chemistry and its Applications, Wiley, New York, 1988, pp. 358 & 365.
Jordan V. C., Cancer cell 5(3) 207-13,2000.

Affiliated with

Also associated with

Rating

Piperazinyltriazines as estrogen receptor modulators does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Piperazinyltriazines as estrogen receptor modulators, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Piperazinyltriazines as estrogen receptor modulators will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3424108